prikaz prve stranice dokumenta Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
No public access
Scientific paper - Original scientific paper
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
Expert opinion on biological therapy, 17 (2017), 8; 915-926. https://doi.org/10.1080/14712598.2017.1341486
Inotai, András; Prins, Christiaan; Csanádi, Marcell; Vitezić, Dinko; Codreanu, Catalin; Kaló, Zoltán

Cite this document

Inotai, A., Prins, C., Csanádi, M., Vitezić, D., Codreanu, C. & Kaló, Z. (2017). Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert opinion on biological therapy, 17. (8), 915-926. doi: 10.1080/14712598.2017.1341486

Inotai, András, et al. "Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars." Expert opinion on biological therapy, vol. 17, no. 8, 2017, pp. 915-926. https://doi.org/10.1080/14712598.2017.1341486

Inotai, András, Christiaan Prins, Marcell Csanádi, Dinko Vitezić, Catalin Codreanu and Zoltán Kaló. "Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars." Expert opinion on biological therapy 17, no. 8 (2017): 915-926. https://doi.org/10.1080/14712598.2017.1341486

Inotai, A., et al. (2017) 'Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars', Expert opinion on biological therapy, 17(8), pp. 915-926. doi: 10.1080/14712598.2017.1341486

Inotai A, Prins C, Csanádi M, Vitezić D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert opinion on biological therapy [Internet]. 2017 [cited 2024 November 20];17(8):915-926. doi: 10.1080/14712598.2017.1341486

A. Inotai, C. Prins, M. Csanádi, D. Vitezić, C. Codreanu and Z. Kaló, "Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars", Expert opinion on biological therapy, vol. 17, no. 8, pp. 915-926, 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:992083. [Accessed: 20 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
AuthorAndrás Inotai
AuthorChristiaan Prins
AuthorMarcell Csanádi
AuthorDinko Vitezić
AuthorCatalin Codreanu
AuthorZoltán Kaló
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well- accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleExpert opinion on biological therapy
Numberingvol. 17, no. 8, pp. 915-926
p-ISSN1471-2598
DOIhttps://doi.org/10.1080/14712598.2017.1341486
URN:NBNurn:nbn:hr:184:992083
Publication2017
ProjectNumber: 062-0620063-0060
Title (croatian): Uporaba kardiovaskularnih lijekova i značaj farmakoekonomskih procjena
Title (english): Cardiovascular drugs usage and the importance of pharmacoeconomic evaluations
Leader: Dinko Vitezić
Jurisdiction: Croatia
Funding stream: ZP
Document URLhttp://bib.irb.hr/881000
Type of resourceText
Access conditionsClosed access
Terms of useLicence In copyright icon
Created on2022-02-23 17:24:04